The bank estimates weight loss drug sales in the three countries could more than triple from about $6.6 billion today over the next decade.
Recap by typeshit. Post by @insights_success on Instagram.
The first four weeks cost around 129,800 won at supply price. Hanmi reports 9.75% average weight loss over 40 weeks and has set a 100 billion won first-year sales target.
Miller credits a 25% drop in weight with yearly savings in healthcare spending per person and brings up retatrutide's results.
Prof Jeanne Lubbe and Discovery Health weigh in. Discovery says GLP-1 claims tripled from 2022 to 2025, with members claiming for 5.4 months on average.
A guide to employer plans, Medicare Part D's weight-loss exclusion, Medicaid and paying cash, plus how added uses like sleep apnea open coverage.
The American College of Obstetricians and Gynecologists has issued new guidance, and she walks CBS News viewers through what it means for patients.
The NEJM study of 2,339 people without diabetes also found less knee osteoarthritis pain and fewer sleep apnea events on the drug than on placebo.
Loading…